StockNews.com Initiates Coverage on NeuroMetrix (NASDAQ:NURO)

Investment analysts at StockNews.com began coverage on shares of NeuroMetrix (NASDAQ:NURO) in a note issued to investors on Saturday. The brokerage set a “sell” rating on the medical device company’s stock.

NeuroMetrix Stock Up 1.6 %

NURO stock opened at $4.58 on Friday. The firm has a market capitalization of $9.21 million, a PE ratio of -0.73 and a beta of 2.29. NeuroMetrix has a twelve month low of $2.66 and a twelve month high of $5.56. The stock has a 50-day simple moving average of $3.88 and a two-hundred day simple moving average of $3.86.

NeuroMetrix (NASDAQ:NURO) last posted its earnings results on Tuesday, August 6th. The medical device company reported ($0.74) earnings per share for the quarter. NeuroMetrix had a negative net margin of 181.04% and a negative return on equity of 41.74%. The company had revenue of $0.77 million for the quarter.

NeuroMetrix Company Profile

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.